

To: House Judiciary Committee

From: Gally Public Affairs on behalf of Indivior

Date: March 5, 2024

Re: Proposed Amendment to **HB 203 Correctional Services - Local Detention Centers - Reporting on Opioid Use Disorder**

The following amendment is a sponsor amendment to HB 1031 Correctional Services - Medication-Assisted Treatment (Delegate J. Lewis). This amendment acknowledges a new class of treatment that was not as material when Medication-Assisted Treatment in jails legislation was originally enacted.

In the event the Committee chooses to include Medication-Assisted Treatment in jails funding in HB 203 instead of advancing HB 1031, please include this amendment in HB 203.

AMENDMENT

On page 3, in line 23, after “partial opioid agonist” insert “**(TRANSMUCOSAL AND LONG ACTING INJECTABLE)**”

The amended text would read:

Each local correctional facility shall make available at least one formulation of each FDA–approved full opioid agonist, partial opioid agonist (**TRANSMUCOSAL AND LONG ACTING**), and long–acting opioid antagonist used for the treatment of opioid use disorders.

If you have any questions, please reach out to Eric Gally at 301.251.8710 (cell).